Published in Am J Transplant on August 01, 2014
CD28 Costimulation: From Mechanism to Therapy. Immunity (2016) 0.90
The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation (2016) 0.79
Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol (2016) 0.79
Impact of Immune-Modulatory Drugs on Regulatory T Cell. Transplantation (2016) 0.77
Protecting the Kidney in Liver Transplant Recipients: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant (2016) 0.77
Belatacept: is there BENEFIT for liver transplantation too? Am J Transplant (2014) 0.75
Ubiquitous LEA29Y Expression Blocks T Cell Co-Stimulation but Permits Sexual Reproduction in Genetically Modified Pigs. PLoS One (2016) 0.75
Refractory T-Cell Anergy and Rapidly Fatal Progressive Multifocal Leukoencephalopathy After Prolonged CTLA4 Therapy. Open Forum Infect Dis (2017) 0.75
Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants. Front Med (Lausanne) (2017) 0.75
Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection? Transl Gastroenterol Hepatol (2017) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med (2003) 8.47
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant (2010) 5.40
The survival benefit of liver transplantation. Am J Transplant (2005) 5.08
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 4.05
Banff schema for grading liver allograft rejection: an international consensus document. Hepatology (1997) 3.22
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant (2010) 3.05
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant (2011) 1.93
Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant (2012) 1.90
End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation (2001) 1.79
Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl (2002) 1.58
Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology (2010) 1.39
Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation (2002) 1.35
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation (2010) 1.28
Liver antigen-presenting cells. J Hepatol (2010) 1.22
Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis. Transplantation (2001) 1.15
An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation (2010) 1.08
Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc (2003) 1.06
A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl (2001) 0.99
Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant (2010) 0.94
Belatacept: from rational design to clinical application. Transpl Int (2011) 0.93
Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant (1998) 0.92
Management of renal dysfunction in the liver transplant recipient. Curr Opin Organ Transplant (2009) 0.88
Survival benefit after liver transplantation: a single European center experience. Transplantation (2009) 0.88
The kidney in liver transplantation. J Am Soc Nephrol (1993) 0.86
Kidney transplantation after previous liver transplantation: analysis of the organ procurement transplant network database. Transplantation (2011) 0.85
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
Structural basis for the binding of proline-rich peptides to SH3 domains. Cell (1994) 6.34
Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by Gbetagamma. Nature (1998) 6.32
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant (2010) 5.40
The complex and intriguing lives of PIP2 with ion channels and transporters. Sci STKE (2001) 4.45
A type VII myosin encoded by the mouse deafness gene shaker-1. Nature (1995) 3.71
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant (2007) 3.26
Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant (2009) 3.19
Patient, center and geographic characteristics of nationally placed livers. Am J Transplant (2012) 3.16
Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet (1981) 2.92
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
Paternal population history of East Asia: sources, patterns, and microevolutionary processes. Am J Hum Genet (2001) 2.71
A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation. Am J Transplant (2010) 2.69
Survival of recipients of livers from donation after circulatory death who are relisted and undergo retransplant for graft failure. Am J Transplant (2014) 2.67
The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant (2008) 2.48
Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant (2007) 2.46
Immunosuppression, generic drugs and the FDA. Am J Transplant (2011) 2.43
Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet (2001) 2.39
Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration. Mol Biol Cell (1998) 2.39
Chemical and physiological characterization of fluo-4 Ca(2+)-indicator dyes. Cell Calcium (2000) 2.32
Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet (2000) 2.26
Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med (1997) 2.17
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Molecular epidemiology of adhesin and hemolysin virulence factors among uropathogenic Escherichia coli. Infect Immun (1989) 2.12
Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology (1992) 2.09
Shipment of human islets for transplantation. Am J Transplant (2007) 2.01
American Society of Transplant Surgeons transplant center outcomes requirements--a threat to innovation. Am J Transplant (2009) 2.00
Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun (1997) 1.96
Regulatory intramolecular association in a tyrosine kinase of the Tec family. Nature (1997) 1.95
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Borrelia burgdorferi strain-specific Osp C-mediated immunity in mice. Infect Immun (1997) 1.93
A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav (2000) 1.93
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant (2011) 1.93
Choice-making treatment of young children's severe behavior problems. J Appl Behav Anal (1996) 1.93
Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology (1993) 1.92
Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant (2012) 1.90
Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology (1993) 1.90
Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant (2008) 1.86
Total hepatectomy and liver replacement (orthotopic liver transplantation) for primary hepatic malignancy. World J Surg (1982) 1.84
Relationship of necrosis to organ failure in severe acute pancreatitis. Gastroenterology (1997) 1.83
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol (1995) 1.82
Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology (1995) 1.81
Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation. Ann Intern Med (1992) 1.80
OPTN/SRTR 2013 Annual Data Report: liver. Am J Transplant (2015) 1.79
End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation (2001) 1.79
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant (2007) 1.76
Protective and arthritis-resolving activity in sera of mice infected with Borrelia burgdorferi. Clin Infect Dis (1997) 1.74
Intraoperative glove perforation--single versus double gloving in protection against skin contamination. Postgrad Med J (2001) 1.72
Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant (2011) 1.69
Serum-mediated resolution of Lyme arthritis in mice. Lab Invest (1996) 1.68
Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients. Am J Transplant (2006) 1.66
Acquisition and transmission of the agent of human granulocytic ehrlichiosis by Ixodes scapularis ticks. J Clin Microbiol (1998) 1.64
Iron transport in Mycobacterium smegmatis: ferrimycobactin reductase (nad(p)h:ferrimycobactin oxidoreductase), the enzyme releasing iron from its carrier. FEBS Lett (1975) 1.63
Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant (2014) 1.62
Hepatitis C virus not found in fulminant non-A, non-B hepatitis. Ann Intern Med (1991) 1.58
Impact of pretransplant renal function on survival after liver transplantation. Transplantation (1995) 1.58
Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant (2011) 1.56
A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation. Hepatology (1995) 1.56
Dynamic challenges inhibiting optimal adoption of kidney paired donation: findings of a consensus conference. Am J Transplant (2013) 1.55
Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav (1992) 1.54
Readmission to the intensive care unit after liver transplantation. Crit Care Med (2001) 1.54
Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology (1997) 1.54
Decreased risk of graft failure with maternal liver transplantation in patients with biliary atresia. Am J Transplant (2011) 1.54
An assessment of attitudes to, and extent of, the practice of denture marking in South Australia. Aust Dent J (1998) 1.52
Functional analysis of grafts from living donors. Implications for the treatment of older recipients. Ann Surg (1996) 1.51
Metallic stents for the treatment of intrahepatic biliary strictures after liver transplantation. J Vasc Interv Radiol (1996) 1.51
Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant (2015) 1.50
Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant (2012) 1.50
Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology (1998) 1.46
Cognitive performance in pediatric liver transplant recipients. Am J Transplant (2013) 1.46
Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates. J Am Coll Cardiol (1996) 1.45
FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant (2006) 1.45
Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant (2006) 1.44
Appendicectomy under local anaesthesia. Eur J Surg (1999) 1.44
Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy (1996) 1.44
The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant (2009) 1.44
Phosphatidylinositol 4,5-bisphosphate induces actin stress-fiber formation and inhibits membrane ruffling in CV1 cells. J Cell Biol (2001) 1.43
Delta 9-tetrahydrocannabivarin (delta 9-THCV) as a marker for the ingestion of cannabis versus Marinol. J Anal Toxicol (1999) 1.43
Balancing utility and need by means of donor-to-recipient matching: a challenging problem. Am J Transplant (2013) 1.43
The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation (1995) 1.43
De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. Liver Transpl Surg (1998) 1.42
Negative words on surgical wards result in therapeutic failure of patient-controlled analgesia and further release of cortisol after abdominal surgeries. Minerva Anestesiol (2008) 1.41
The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation (1992) 1.41
Effect of pentoxifylline on hepatic ischemia and reperfusion injury. Surgery (1997) 1.41
Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology (1998) 1.41
The galE gene of Campylobacter jejuni is involved in lipopolysaccharide synthesis and virulence. Infect Immun (2000) 1.41
Structure of dehydroquinate synthase reveals an active site capable of multistep catalysis. Nature (1998) 1.41
Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology (1992) 1.41
Preferred genetic evolutionary sequences in human breast cancer: a case study. Cytometry (1995) 1.40
Waking the dead. Lancet (2001) 1.39
Effect of 24-h blood pressure levels and circadian blood pressure rhythm on left ventricular structure and function in isolated systolic hypertension. Int J Cardiol (1994) 1.39
A procedure to overcome interferences caused by the adulterant "Klear" in the GC-MS analysis of 11-nor-delta9-THC-9-COOH. J Anal Toxicol (1997) 1.39
Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation (2001) 1.38